Logo
header-publicacoes-cientificas.jpg
Artigos Científicos

Delta variant and mRNA Covid-19 vaccines effectiveness: higher odds of vaccine infecti...

22 agosto 2021
link

Copiado!

Delta variant and mRNA Covid-19 vaccines effectiveness: higher odds of vaccine infection breakthroughs

Irina Kislaya, View ORCID ProfileEduardo Freire Rodrigues, View ORCID ProfileVítor Borges, View ORCID ProfileJoão Paulo Gomes, Carlos Sousa, José Pedro Almeida, View ORCID ProfileAndré Peralta-Santos, View ORCID ProfileBaltazar Nunes

Abstract

The SARS-CoV-2 Delta variant (B.1.617.2), initially identified in India, has become predominant in several countries, including Portugal. Few studies have compared the effectiveness of mRNA vaccines against Delta versus Alpha variant of concern (VOC) and estimated variant-specific viral loads in vaccine infection breakthroughs cases. In the context of Delta dominance, this information is critical to inform decision-makers regarding the planning of restrictions and vaccination roll-out.

Results

Of the 2 097 SARS-CoV-2 RT-PCR positive cases included in the analysis, 966 (46.1%) were classified with WGS and 1131 (53.9%) with SGTF. Individuals infected with the Delta variant were more frequently vaccinated 162 (12%) than individuals infected with the Alpha variant 38 (5%). We report a statistically significant higher odds of vaccine infection breakthrough for partial (OR=1.70; CI95% 1.18 to 2.47) and complete vaccination (OR=1.96; CI95% 1.22 to 3.14) in the Delta cases when compared to the Alpha cases, suggesting lower mRNA vaccine effectiveness against Delta cases. On our secondary analysis, we observed lower mean Ct values for the Delta VOC cases versus Alpha, regardless the vaccination status. Additionally, the Delta variant cases revealed a Ct-value mean increase of 2.24 (CI95% 0.85 to 3.64) between unvaccinated and fully vaccinated breakthrough cases contrasting with 4.49 (CI95% 2.07 to 6.91) in the Alpha VOC, suggesting a lower impact of vaccine on viral load of Delta cases.

Newsletter

Quer ficar a par das novidades?
Subscreva a newsletter!

PessoasCiênciaSaúde

Escolha do ConsumidorGlobal Safe SiteLivro de Reclamações

Contactos

+351 222 401 401
Custo de chamada
para a rede fixa nacional
2ª a 6ª – 8h00 às 20h00
Sábado – 8h30 às 12h30

Siga-nos nas redes sociais

APP Saúde Unilabs

© Unilabs 2026 | Powered by  
.
.
check